Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004845 · ClinicalTrials.gov registry record · Phase 2

A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)

A Phase 2 study of Alzheimer Disease, sponsored by National Institute on Aging (NIA).

Completed
Registry status
Phase 2
Development phase
20
Study locations

NCT00004845: Completed Phase 2 study of Alzheimer Disease, sponsored by National Institute on Aging (NIA).

NCT00004845 is a Phase 2 study of Alzheimer Disease that has completed, run by National Institute on Aging (NIA). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004845, a Phase 2 study of Alzheimer Disease, has completed, sponsored by National Institute on Aging (NIA).

COMPLETED
Registry status
Phase 2
Development phase
20
Study locations

Study Summary

The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG Naproxen
  • DRUG Rofecoxib

Study Locations (20)

Florida

  • Baumel-Eisner Neuromedical Institute, Boca Raton - Boca Raton
  • Baumel-Eisner Ft Lauderdale - Fort Lauderdale
  • Mayo Clinic Jacksonville - Jacksonville
  • Wein Center - Miami Beach
  • Baumel-Eisner Neuromedical Institute, MiamiBeach - Miami Beach
  • University of South Florida - Tampa
  • Premiere Research Institute - West Palm Beach

California

  • University of California Irvine Institute for Brain Aging and Dementia - Irvine
  • University of California, San Diego - La Jolla
  • University of Southern California - Los Angeles
  • University of California, Los Angeles - Los Angeles
  • University of California, Davis - Martinez

Arizona

  • Barrow Neurological Group - Phoenix
  • University of Arizona, Tucson - Tucson

Connecticut

  • Yale University, School of Medicine - New Haven

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Georgia

  • Emory University - Atlanta

Illinois

  • Rush Presbyterian St. Luke's Medical Center - Chicago

Indiana

  • Indiana University Medical Center - Indianapolis

Trial Details

FieldValue
Est. Completion 2001-12
Phase Phase 2
National Institute on Aging (NIA)

131 total trials

What the finished NCT00004845 record still lists

NCT00004845 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Naproxen is the first listed.

NCT00004845 names 20 study sites across 9 states, led by Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT00004845 about?

NCT00004845 is a clinical study titled "A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)". The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.

What is the current status of trial NCT00004845?

This trial is currently completed. It is a Phase 2 study. Estimated completion is 2001-12.

What conditions does trial NCT00004845 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT00004845?

The interventions under investigation include: Naproxen (DRUG), Rofecoxib (DRUG).

Who is sponsoring clinical trial NCT00004845?

This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004845 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00004845, the US trial registry maintained by the National Library of Medicine. NCT00004845 (unsized enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.